Interaction of Body Mass Index and Glycemic Status on Cardiovascular Outcomes in Patients With Cancer Treated With Anthracyclines

QR Code

Interaction of Body Mass Index and Glycemic Status on Cardiovascular Outcomes in Patients With Cancer Treated With Anthracyclines

Background Anthracycline‐based chemotherapy is a vital treatment for various cancers but carries notable risks of cardiotoxicity. This study aimed to assess how different body mass index values and glycemic status influence the risk of major adverse cardiovascular events (MACE) in chemotherapy‐naïve...

Full description

Saved in:

Bibliographic Details
Main Authors:	Iokfai Cheang, Xu Zhu, Xinyi Lu, Ying Li, Gehui Ni, Ying Yang, Yue Zhang, Qing‐Wen Ren, Mei‐Zhen Wu, Rongrong Gao, Kai‐Hang Yiu, Xinli Li
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	anthracycline‐based chemotherapy body mass index cardiotoxicity cardiovascular outcomes glycemic status heart failure
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.124.040876
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity
by: Rongrong Bai, et al.
Published: (2025-06-01)

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
by: G. R. Ramazanov, et al.
Published: (2023-01-01)

Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis
by: Ling Yin Fritz Wong, et al.
Published: (2025-07-01)

RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS
by: N. T. Vatutin, et al.
Published: (2017-10-01)

Genetic basis of anthracyclines cardiotoxicity: Literature review
by: M. Yu. Sinitsky, et al.
Published: (2021-10-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
by: Yu. V. Vasyuk, et al.
Published: (2017-05-01)

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
by: Luigi Spadafora, et al.
Published: (2025-06-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
by: A. T. Teplyakov, et al.
Published: (2019-03-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

Roles of Non-Coding RNA in Anthracycline Cardiotoxicity: A Narrative Review
by: Xiao S, et al.
Published: (2025-07-01)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
by: D. A. Andreev, et al.
Published: (2024-03-01)

Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
by: A. A. Avagimyan, et al.
Published: (2021-11-01)

CHANGE OF THE LEFT VENTRICLE FUNCTIONING IN LYMPHOMA TREATED WITH ANTHRACYCLINE ANTIBIOTICS
by: K. V. Shuykova, et al.
Published: (2016-01-01)

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity
by: V. D. Levina, et al.
Published: (2022-12-01)

Changes in left ventricular systolic and diastolic function after chemotherapy for breast cancer with doxorubicin
by: I. A. Karput, et al.
Published: (2024-01-01)

Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy
by: A.-S. O. Bady, et al.
Published: (2020-05-01)

Course of arterial hypertension during breast cancer chemotherapy with anthracyclines
by: E. N. Berezikova, et al.
Published: (2024-10-01)

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases
by: E. V. Grakova, et al.
Published: (2023-01-01)

Ejection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
by: Rizkyastari Onny, et al.
Published: (2025-06-01)

Predictive and Prognostic Relevance of ABC Transporters for Resistance to Anthracycline Derivatives
by: Rümeysa Yücer, et al.
Published: (2025-07-01)

Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer: A non-inferiority meta-analysis
by: Fabio Girardi, et al.
Published: (2025-10-01)

Cardioprotective effect of thiotriazoline in cancer patients
by: A. V. Koltsov, et al.
Published: (2023-02-01)

RADIONUCLIDE METHODS IN THE DETECTION AND FORECAST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS
by: V. I. Chernov, et al.
Published: (2016-12-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01)

Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
by: L. M. Kogoniya, et al.
Published: (2022-07-01)

Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01)

CHEMOTHERAPY CARDIOTOXICITY SCREENING WITH CARDIAC TROPONINS
by: O. V. Krikunova, et al.
Published: (2015-12-01)

Prognostic value of humoral markers in patients with anthracycline-related cardiac dysfunction
by: E. V. Grakova, et al.
Published: (2023-10-01)

Natural strategies of preventing anthracycline-induced cardiotoxicity – a review
by: Anca STOICA, et al.
Published: (2022-12-01)

DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST
by: T. Yu. Semiglazova, et al.
Published: (2017-09-01)

Effect of fruit ripening stage on glycemic index, glycemic load and antioxidant properties in healthy subjects: implications for the nutritional management of diabetes
by: Béda Franck Yapo, et al.
Published: (2025-12-01)

Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity
by: I. T. Murkamilov, et al.
Published: (2021-03-01)

Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
by: Yu. A. Vasyuk, et al.
Published: (2021-10-01)

Analysis of arterial stiffness parameters in breast cancer patients undergoing combination anthracycline-containing chemotherapy
by: E. G. Medvedeva, et al.
Published: (2025-05-01)

Risk factors and prevention of cardiovascular complications in breast cancer
by: M. N. Mamedov, et al.
Published: (2025-02-01)

The impact of a complete nutrition diabetic formula on glycemic control and nutritional status in hospitalized patients with diabetes mellitus
by: Chin-Kun Wang, et al.
Published: (2025-07-01)

Longitudinal Assessment of QT Apex in Tumor‐Bearing Dogs Receiving Doxorubicin Monotherapy
by: Keita Kitagawa, et al.
Published: (2025-07-01)